恩塞芬汀核磁共振波谱学数据解析OA
Detailed NMR Assignment of Ensifentrine
恩塞芬汀(Ensifentrine)于 2024 年 6 月被 FDA 批准上市.现有文献只有该药物的核磁共振(NMR)波谱数据,缺乏详细的原子归属,这不利于恩塞芬汀的杂质鉴定和质量控制,且该化合物存在多个季碳和氮原子,在 NMR 信号归属上存在一定难点.本文利用 Bruker Avance III 400 MHz NMR 波谱仪,获得恩塞芬汀的 1H、13C 以及二维 NMR 谱,完整归属了该化合物的 1H 和 13C NMR 信号.与现有文献不同的是,本文用 DMSO-d6做溶剂,提高了样品溶解度,可准确指认活泼氢信号的耦合关系,同时使样品的二维 NMR 谱信号清晰可辨.本文为基于 NMR 波谱学的恩塞芬汀原料药结构解析、含量测定和质量控制提供了研究基础.
Ensifentrine was approved for marketing by the U.S.Food and Drug Administration(FDA)in June 2024.To date,however,the literature has provided only the raw NMR spectral data of this drug without detailed signal assignments,which hinders impurity identification and quality control for ensifentrine.Furthermore,the compound contains multiple quaternary carbon and nitrogen atoms,presenting challenges in assigning NMR signals.In this study,we employed a Bruker Avance III 400 MHz NMR spectrometer to acquire 1H,13C,and two-dimensional NMR spectra of ensifentrine,and fully assigned all 1H and 13C signals.Notably,unlike previous reports,we utilized DMSO-d6 as the solvent,which enhanced sample solubility,permitted unambiguous identification of the coupling relationships of active hydrogen signals,and yielded well-resolved two-dimensional NMR spectra.This work provides a reference for NMR-based structural analysis,content determination,and quality control of the active pharmaceutical ingredient(API)ensifentrine.
潘美红;秦楠;赵川;文柳静
天津医科大学药学院,天津 300070天津医科大学药学院,天津 300070天津医科大学基础医学院,天津 300070天津医科大学肿瘤医院,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津 300060
数理科学
恩塞芬汀结构解析核磁共振二维核磁共振
ensifentrinestructural analysisnuclear magnetic resonance(NMR)two-dimensional NMR spectroscopy
《波谱学杂志》 2026 (3)
339-349,11
天津医科大学基础医学院青年教师科研孵育基金项目(2023FY04)天津医科大学肿瘤医院药物成药性评价与系统转化全国重点实验室资助项目(QZ23-5和QZKF24-5).
评论